FDA's monitoring of postmarketing studies probed

被引：0

|

作者：

Young, Donna

机构：

来源：

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY | 2006年 / 63卷 / 16期

关键词：

D O I：

10.2146/news060003

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

[No abstract available]

引用

收藏

页码：1485 / 1486

页数：2

相关论文

共 50 条

[1] The FDA's poor oversight of postmarketing studies
不详
[J]. LANCET, 2009, 374 (9701): : 1568 - 1568
[2] FDA Oversight of Postmarketing Studies
Kashoki, Mwango
Lee, Cathryn
Stein, Peter
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (12): : 1201 - 1202
[3] FDA Increases Focus on Postmarketing Studies
Goozner, Merrill
[J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (17) : 1302 - U17
[4] FDA faces criticism for its postmarketing study monitoring
Mitka, Mike
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (08): : 921 - 921
[5] FDA's postmarketing review of varenicline and bupropion
[J]. Reactions Weekly, 2009, 1236 (1) : 3 - 3
[6] A review of pregnancy and lactation postmarketing studies required by the FDA
Krastein, Jason
Sahin, Leyla
Yao, Lynne
[J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 (03) : 287 - 297
[7] CORRUPTION PROBED AT CHINA'S FDA
不详
[J]. CHEMICAL & ENGINEERING NEWS, 2010, 88 (25) : 17 - 17
[8] FDA will increase postmarketing surveillance of drugs
Tanne, JH
[J]. BRITISH MEDICAL JOURNAL, 2004, 329 (7476): : 1203 - 1203
[9] A proposal for financing postmarketing drug safety studies by augmenting FDA user fees
Carpenter, D
[J]. HEALTH AFFAIRS, 2005, 24 (06) : W5469 - W5480
[10] FDA's Unimproved Enforcement of Postmarketing Requirements and Commitments: Implications for Providers and Patients
Dauner, Daniel G.
Dauner, Kim Nichols
Peterson, Annalisa L. H.
[J]. RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2020, 16 (06): : 844 - 847

← 1 2 3 4 5 →